Company Number: 14384077

Analysis Date: 2025-07-20 12:22 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Ferrous Pharma Ltd is a newly incorporated micro-entity operating in the dispensing chemist niche. Its financials indicate very modest net assets (£1,287 as of 30 September 2024) and a significant reduction in working capital compared to the prior year (from £9,523 to £1,287). While the company remains solvent with positive net current assets, the sharp decrease signals a tightening liquidity position. Given the limited trading history and small scale, credit should be extended cautiously, with conditions such as regular financial monitoring and possibly restricting credit limits until financial stability improves.

2. Financial Strength
   The balance sheet shows a very lean structure typical of a micro-entity. Current assets are stable at around £36.6k, but current liabilities have increased substantially from £26.9k to £35.4k, eroding net assets and working capital. No fixed assets or long-term liabilities are reported, indicating no tangible asset backing or long-term leverage. Shareholders’ funds have decreased proportionally, reflecting retained losses or distributions. The financial position is fragile, with minimal cushion to absorb shocks or support expansion.

3. Cash Flow Assessment
   The small positive net current assets imply marginal liquidity, sufficient only for immediate operational needs. The increase in current liabilities suggests rising short-term obligations which could pressure cash flow. The sole director is actively involved, but there is no evidence of external financing or significant cash reserves. Working capital management will be critical, and the company may face challenges in scaling or meeting unexpected expenses without additional capital injections or improved receivables turnover.

4. Monitoring Points

• Net current assets and liquidity trends in subsequent reporting periods
• Changes in current liabilities and ability to meet short-term obligations promptly
• Profitability and cash flow generation to rebuild reserves
• Director’s management of working capital and cost control
• Any new financing, credit lines, or shareholder funding that strengthens capital base